^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    COMPANY:
    Circulogene

    i
    Other names: Circulogene | CirculoGene Theranostics
    Evidence

    News

    over2years
    Research indicates that positive PD-L1 detected by CIRCULOGENE liquid biopsy can have favorable outcomes for cancer patients (PRWeb)
    "CIRCULOGENE’s blood-based test for PD-L1 expression continues to be at the forefront of cancer research, challenging the preeminence of tissue biopsy in informing patient treatment plans...Research led by Dr. Paul Walker and a team of scientists from Brody School of Medicine at East Carolina University was recently published in the Journal of Clinical Oncology as part of the 2023 annual meeting proceedings for the American Society of Clinical Oncology (ASCO)."
    Clinical data
    almost3years
    CIRCULOGENE’s liquid biopsy for PD-L1 status features in research presented at the recent AACR annual meeting (Circulogene Press Release)
    "New research presented by Dr. Lowell Hart at the April 14-19 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida relied upon use of CIRCULOGENE’s technology to identify biomarkers which indicate the efficacy of immune checkpoint inhibitors (ICI) therapy...The research poster, entitled 'Liquid biopsy for PD-L1 status by analysis of cfRNA in pan-cancer cohort: Preliminary clinical data from a large community practice' was presented..."
    Clinical data